[HTML][HTML] Carbapenem-Resistant Klebsiella pneumoniae: Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options

T Karampatakis, K Tsergouli, P Behzadi - Antibiotics, 2023 - mdpi.com
Klebsiella pneumoniae is a Gram-negative opportunistic pathogen responsible for a variety
of community and hospital infections. Infections caused by carbapenem-resistant K …

Klebsiella pneumoniae carbapenemase variants: the new threat to global public health

L Ding, S Shen, J Chen, Z Tian, Q Shi… - Clinical Microbiology …, 2023 - Am Soc Microbiol
Klebsiella pneumoniae carbapenemase (KPC) variants, which refer to the substitution,
insertion, or deletion of amino acid sequence compared to wild bla KPC type, have reduced …

Colistin monotherapy versus combination therapy for carbapenem-resistant organisms

KS Kaye, D Marchaim, V Thamlikitkul, Y Carmeli… - NEJM …, 2022 - evidence.nejm.org
Background Pneumonia and bloodstream infections (BSI) due to extensively drug-resistant
(XDR) Acinetobacter baumannii, XDR Pseudomonas aeruginosa, and carbapenem …

Mortality attributable to bloodstream infections caused by different carbapenem-resistant gram-negative bacilli: results from a nationwide study in Italy (ALARICO …

M Falcone, G Tiseo, S Carbonara… - Clinical Infectious …, 2023 - academic.oup.com
Background Our aim was to analyze mortality attributable to carbapenem-resistant (CR)
gram-negative bacilli (GNB) in patients with bloodstream infections (BSIs). Methods …

[HTML][HTML] Guidelines for the diagnosis, treatment, prevention and control of infections caused by carbapenem-resistant gram-negative bacilli

M Zeng, J Xia, Z Zong, Y Shi, Y Ni, F Hu, Y Chen… - Journal of Microbiology …, 2023 - Elsevier
The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global
public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug …

[HTML][HTML] Cefiderocol, a siderophore cephalosporin, as a treatment option for infections caused by carbapenem-resistant Enterobacterales

KS Kaye, T Naas, JM Pogue, GM Rossolini - Infectious Diseases and …, 2023 - Springer
Carbapenem-resistant Enterobacterales (CRE) remain a significant public health threat,
and, despite recent approvals, new antibiotics are needed. Severe infections caused by …

[HTML][HTML] Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence

P Viale, CE Sandrock, P Ramirez, GM Rossolini… - Annals of intensive …, 2023 - Springer
Appropriate antibiotic treatment for critically ill patients with serious Gram-negative infections
in the intensive care unit is crucial to minimize morbidity and mortality. Several new …

Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with …

M Gatti, F Pea - Expert Review of Anti-infective Therapy, 2023 - Taylor & Francis
Introduction The choice of best therapeutic strategy for difficult-to-treat resistance (DTR)
Gram-negative infections currently represents an unmet clinical need. Areas covered This …

Defining the optimal duration of therapy for hospitalized patients with complicated urinary tract infections and associated bacteremia

J McAteer, JH Lee, SE Cosgrove… - Clinical Infectious …, 2023 - academic.oup.com
Background Limited data are available to guide effective antibiotic durations for hospitalized
patients with complicated urinary tract infections (cUTIs). Methods We conducted an …

[HTML][HTML] Pharmacokinetic/pharmacodynamic analysis of continuous-infusion fosfomycin in combination with extended-infusion cefiderocol or continuous-infusion …

M Gatti, M Giannella, M Rinaldi, P Gaibani, P Viale… - Antibiotics, 2022 - mdpi.com
Objectives: To perform a pharmacokinetic/pharmacodynamic (PK/PD) analysis of continuous-
infusion (CI) fosfomycin combined with extended-infusion (EI) cefiderocol or CI ceftazidime …